[1] Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors. Adv Cancer Res, 2004, 91: 137-168.  doi: 10.1016/S0065-230X(04)91004-4
[2] Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics, 2011, 3(2): 145-155.  doi: 10.2217/epi.11.12
[3] Marchion DC, Bicaku E, Daud AI, et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res, 2005, 65(9): 3815-3822.  doi: 10.1158/0008-5472.CAN-04-2478
[4] Rajendran P, Ho E, Williams DE, et al. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics, 2011, 3(1): 4.
[5] Wang H, Zhou W, Zheng Z, et al. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair(Amst), 2012, 11(2): 146-156.  doi: 10.1016/j.dnarep.2011.10.014
[6] Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA, 2010, 107(33): 14639-14644.  doi: 10.1073/pnas.1008522107
[7] Falk M, Lukásová E, Kozubek S. Chromatin structure influences the sensitivity of DNA to gamma-radiation. Biochim Biophys Acta, 2008, 1783(12): 2398-2414.  doi: 10.1016/j.bbamcr.2008.07.010
[8] Storch K, Eke I, Borgmann K, et al. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res, 2010, 70(10): 3925-3934.  doi: 10.1158/0008-5472.CAN-09-3848
[9] Adimoolam S, Sirisawad M, Chen J, et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA, 2007, 104(49): 19482-19487.  doi: 10.1073/pnas.0707828104
[10] Chinnaiyan P, Cerna D, Burgan WE, et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res, 2008, 14(17): 5410-5415.  doi: 10.1158/1078-0432.CCR-08-0643
[11] Zhang F, Zhang T, Teng ZH, et al. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer(NSCLC)cells. Cancer Biol Ther, 2009, 8(9): 823-831.  doi: 10.4161/cbt.8.9.8143
[12] Baschnagel A, Russo A, Burgan WE, et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther, 2009, 8(6): 1589-1595.  doi: 10.1158/1535-7163.MCT-09-0038
[13] Kuribayashi T, Ohara M, Sora S, et al. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med, 2010, 25(1): 25-29.
[14] Deorukhkar A, Shentu S, Park HC, et al. Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas, 2010, 39(8): 1277-1283.
[15] Blattmann C, Oertel S, Ehemann V, et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys, 2010, 78(1): 237-245.  doi: 10.1016/j.ijrobp.2010.03.010
[16] Kachhap SK, Rosmus N, Collis SJ, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One, 2010, 5(6): e11208.  doi: 10.1371/journal.pone.0011208
[17] Konsoula Z, Cao H, Velena A, et al. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. Int J Radiat Oncol Biol Phys, 2011, 79(5): 1541-1548.  doi: 10.1016/j.ijrobp.2010.11.057
[18] Mueller S, Yang X, Sottero TL, et al. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett, 2011, 306(2): 223-229.  doi: 10.1016/j.canlet.2011.03.010
[19] Koprinarova M, Botev P, Russev G. Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair(Amst), 2011, 10(9): 970-977.  doi: 10.1016/j.dnarep.2011.07.003
[20] Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat(PRAVO)phase 1 study. Lancet Oncol, 2010, 11(5): 459-464.  doi: 10.1016/S1470-2045(10)70058-9